AbbVie 2014 Annual Report Download - page 66

Download and view the complete annual report

Please find page 66 of the 2014 AbbVie annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 182

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180
  • 181
  • 182

13NOV201221352027
AbbVie Inc. and Subsidiaries
Consolidated Statements of Equity
Accumulated
Common Additional other Net parent
years ended December 31 shares Common Treasury paid-in comprehensive Retained company
(in millions) outstanding stock stock capital loss earnings investment Total
Balance at December 31, 2011 $ $ $ $ (25) $ $ 11,957 $ 11,932
Net earnings 5,275 5,275
Net transactions with Abbott
Laboratories (13,519) (13,519)
Assumption of accumulated
unrealized losses on pension and
other post-employment benefits,
net of tax benefit of $36 (296) (296)
Other comprehensive loss, net of tax (29) (29)
Balance at December 31, 2012 (350) 3,713 3,363
Separation-related adjustments (1,316) (662) 707 (1,271)
Reclassification of parent company
net investment in connection with
separation 4,420 — (4,420)
Issuance of common stock at
separation 1,577 16 — (16)
Net earnings 4,128 4,128
Other comprehensive income, net of
tax 570 — 570
Dividends declared (2,561) (2,561)
Share repurchases (4) (223) (223)
Stock-based compensation plans and
other 14 (97) 583 486
Balance at December 31, 2013 1,587 16 (320) 3,671 (442) 1,567 4,492
Net earnings 1,774 1,774
Other comprehensive loss, net of tax (1,589) (1,589)
Dividends declared (2,806) (2,806)
Share repurchases (9) (550) (550)
Stock-based compensation plans and
other 13 — (102) 523 421
Balance at December 31, 2014 1,591 $16 $(972) $ 4,194 $(2,031) $ 535 $ $ 1,742
The accompanying notes are an integral part of these consolidated financial statements.
60 2014 Form 10-K